A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer
- PMID: 10632423
- DOI: 10.1016/s0015-0282(99)00450-1
A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer
Abstract
Objective: To compare the efficacy and tolerability of two recombinant human FSH (r-hFSH) preparations, follitropin-alpha (Gonal-F; Ares Serono, Geneva, Switzerland) and follitropin-beta (Puregon; Organon, Oss, the Netherlands), for superovulation in patients undergoing IVF-ET.
Design: Randomized, parallel-group, assessor-blind, single-center trial.
Setting: Outpatient tertiary referral center for assisted reproductive techniques.
Patient(s): Forty-four infertile women undergoing IVF-ET.
Intervention(s): After down-regulation with buserelin acetate, patients were randomized to receive follitropin-alpha or follitropin-beta, 150 IU/d for 6 days; after that, dosages were adjusted according to the ovarian response.
Main outcome measure(s): Cumulative dose of r-hFSH; duration of r-hFSH treatment; number of follicles of > or =11 mm and of 14 mm on day 7 of r-hFSH treatment and on the day of hCG administration; number of oocytes retrieved; number of viable embryos; and number of pregnancies (biochemical, ectopic, miscarried) and clinical pregnancies.
Result(s): There were no statistically significant differences in any efficacy measures between the two preparations. The incidence of systemic adverse events was comparable in the two groups. Local reactions at the injection site were significantly more common and more severe with follitropin-beta than with follitropin-alpha
Conclusion(s): Follitropin-alpha and follitropin-beta have comparable efficacy in patients undergoing IVF-ET.
Similar articles
-
Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any difference?Fertil Steril. 2009 Apr;91(4 Suppl):1522-5. doi: 10.1016/j.fertnstert.2008.08.112. Epub 2008 Oct 11. Fertil Steril. 2009. PMID: 18851846
-
A comparison of the efficacy, tolerability, and convenience of two formulations of follitropin-alpha in Iranian woman undergoing intracytoplasmic sperm injection cycles.Fertil Steril. 2008 Oct;90(4):1043-8. doi: 10.1016/j.fertnstert.2007.08.001. Epub 2007 Dec 3. Fertil Steril. 2008. PMID: 18053995 Clinical Trial.
-
Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.Hum Reprod. 1997 Oct;12(10):2133-9. doi: 10.1093/humrep/12.10.2133. Hum Reprod. 1997. PMID: 9402268 Clinical Trial.
-
Outcomes of new quality standards of follitropin alfa on ovarian stimulation: meta-analysis of previous studies.BioDrugs. 2009;23(1):37-42. doi: 10.2165/00063030-200923010-00004. BioDrugs. 2009. PMID: 19344190 Review.
-
Follicle-stimulating hormone in clinical practice: an update.Treat Endocrinol. 2004;3(3):161-71. doi: 10.2165/00024677-200403030-00004. Treat Endocrinol. 2004. PMID: 16026112 Review.
Cited by
-
Recombinant follitropin alfa/lutropin alfa in fertility treatment.Biologics. 2010 Feb 4;4:5-17. Biologics. 2010. PMID: 20161981 Free PMC article.
-
Comparison of DNA damage in granulosa cells of women undergoing controlled ovarian stimulation in in vitro fertilization protocols with the recombinant human follicle-stimulating hormones Corneumon®, Gonal-F®, Pergoveris® and Puregon®: a randomized trial.Arch Gynecol Obstet. 2024 May;309(5):2107-2114. doi: 10.1007/s00404-024-07392-7. Epub 2024 Mar 5. Arch Gynecol Obstet. 2024. PMID: 38441601 Clinical Trial.
-
The Development of Gonadotropins for Clinical Use in the Treatment of Infertility.Front Endocrinol (Lausanne). 2019 Jul 3;10:429. doi: 10.3389/fendo.2019.00429. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31333582 Free PMC article. Review.
-
A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment.J Assist Reprod Genet. 2005 Feb;22(2):81-8. doi: 10.1007/s10815-005-1497-1. J Assist Reprod Genet. 2005. PMID: 15844733 Free PMC article. Clinical Trial.
-
Glycosylation Pattern and in vitro Bioactivity of Reference Follitropin alfa and Biosimilars.Front Endocrinol (Lausanne). 2019 Jul 24;10:503. doi: 10.3389/fendo.2019.00503. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31396162 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
